IMVT-1401-2501: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD)
Latest Information Update: 23 May 2025
At a glance
- Drugs Batoclimab (Primary)
- Indications Graves' disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Immunovant
Most Recent Events
- 23 May 2025 Last checked against ClinicalTrials.gov record.
- 15 May 2025 Planned number of patients changed from 50 to 35.
- 15 May 2025 Planned End Date changed from 1 May 2025 to 1 Jul 2025.